Tempus AI Inc. (TEM) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Tempus AI Inc. (TEM)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

31.84

-0.50 (-1.55%)

At close: Jan 14, 2025, 3:59 PM

32.17

1.05%

After-hours Jan 14, 2025, 07:59 PM EST

undefined% (undefined)

Bid	31.92
Market Cap	4.85B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-5.16
PE Ratio (ttm)	-6.17
Forward PE	n/a
Analyst	Buy

Ask	32.2
Volume	3,841,908
Avg. Volume (20D)	2,550,296
Open	33.10
Previous Close	32.34
Day's Range	31.66 - 34.62
52-Week Range	22.89 - 79.49
Beta	undefined

About TEM

Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-iden...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Mar 28, 2012

Employees 2,300

Stock Exchange NASDAQ

Ticker Symbol TEM

Website https://www.tempus.com

Analyst Forecast

According to 11 analyst ratings, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 72.77% from the latest price.

Buy 72.73%

Hold 27.27%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 day ago · Source New

-13.81%

Tempus AI shares are trading lower after the compa... Unlock content with Pro Subscription

2 months ago · Source

-10.1%

Tempus AI shares are trading lower after the company reported mixed Q3 financial results. Also, the company announced it entered into an agreement to acquire Ambry Genetics.

News

1 day ago · businesswire.com

Tempus Announces Its First-Ever, Whole-Genome Sequencing Assay, xH

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its f...

3 days ago · 247wallst.com

2 Stocks Cathie Wood Is Swinging For the Fences With

Investing guru Cathie Wood remains an investor favorite.

5 days ago · zacks.com

Tempus AI Stock Falls Despite Collaboration Announcement With Genialis

TEM announces a collaboration with Genialis to develop new RNA-based algorithms across cancer types.

6 days ago · businesswire.com

Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, ...

1 week ago · zacks.com

Tempus AI Stock Surges 23% in 6 Months: Should You Snap It Up Now?

TEM's cutting-edge product lines and strategic plans are positioning it for long-term success.

2 weeks ago · zacks.com

5 Top AI-in-MedTech Stocks for Big Gains in 2025: MDT, BSX & More

Here we discuss five medical stocks - MDT, BSX, BDX, GEHC and TEM - incorporating AI in their workflows. These are likely to gain in 2025 as AI helps cut costs and improve patient care.

2 weeks ago · fool.com

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's aggressive growth style of investing may have fallen flat earlier this year, but the co-founder, CEO, and ace stock picker at Ark Invest has been on a roll lately. Ark's most popular exc...

3 weeks ago · zacks.com

Tempus AI Stock Plunges 28.9% in Three Months: What's Next?

TEM is enhancing its offerings and expanding the breadth of products and services to improve patient care. However, macro challenges are likely to hurt its performance.

3 weeks ago · marketbeat.com

Tempus AI: A Potential Double-Bagger After Recent Pullback

In mid-August, around two months after Tempus AI's NASDAQ: TEM initial public offering (IPO), the stock was up a marvelous 93%. However, shares have experienced wild volatility and are now 8% below th...

3 weeks ago · businesswire.com

Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions

CHICAGO--(BUSINESS WIRE)--Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network ...

4 weeks ago · seekingalpha.com

Tempus AI: Recent Weakness Presents Gift Ahead Of The Holidays

Tempus AI has strong long-term potential in healthcare technology, despite recent stock volatility due to lock-up period expiration and insider selling. The company's innovative "Intelligent Diagnosti...

4 weeks ago · businesswire.com

New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by...

1 month ago · seekingalpha.com

Tempus AI: Why I'm Buying This AI Stock

Tempus AI's strategic acquisitions and partnerships, including Ambry Genetics and a JV with SoftBank, bolster its growth and competitive edge in AI health tech. The revenue growth and gross margins fo...

1 month ago · zacks.com

Will Ambry Genetics Acquisition Drive Tempus AI's Prospects?

TEM acquires Ambry Genetics, expanding its testing portfolio and redefining precision medicine.

1 month ago · businesswire.com

Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annu...

1 month ago · youtube.com

The Big 3: CRWD, CVNA, TEM

@ProsperTradingAcademy's Charles Moon is bullish on all of today's Big 3. He points to Crowdstrike's (CRWD) recovery and Carvana (CVNA) coiling to the upside as positive markers but warns of volatilit...

2 months ago · seekingalpha.com

Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation

Tempus AI, Inc. founded in 2015, leverages AI for precision medicine, showing strong growth since its June 2024 listing, presenting a buying opportunity. The company boasts a vast clinical and molecul...

2 months ago · businesswire.com

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Acti...

2 months ago · seekingalpha.com

Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript

Tempus AI, Inc. (NASDAQ:TEM ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Liz Krutoholow – Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer...

2 months ago · businesswire.com

Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted fo...

Load More News